Free tool
FAERS Monitor: Emend
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021549 or its brand name (Emend, Aprepitant). Reports on generic versions are filed under their own applications.
Reports
19,186
Serious
17,114
89% of reports
Hospitalization
10,508
Death reported
3,248
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea2,321
- fatigue2,054
- pyrexia1,734
- dyspnoea1,696
- diarrhoea1,674
- vomiting1,605
- off label use1,489
- alopecia1,412
- rash1,330
- hypersensitivity1,248
- decreased appetite1,172
- pruritus1,138
- febrile neutropenia1,126
- infusion related reaction1,112
- pain1,097
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 127 |
| 2005 | 134 |
| 2006 | 145 |
| 2007 | 181 |
| 2008 | 177 |
| 2009 | 216 |
| 2010 | 351 |
| 2011 | 479 |
| 2012 | 764 |
| 2013 | 691 |
| 2014 | 818 |
| 2015 | 1,057 |
| 2016 | 1,325 |
| 2017 | 894 |
| 2018 | 1,376 |
| 2019 | 1,393 |
| 2020 | 1,186 |
| 2021 | 1,275 |
| 2022 | 1,170 |
| 2023 | 1,246 |
| 2024 | 1,848 |
| 2025 | 1,439 |
| 2026 | 894 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,034,973 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 1,126 | 18.9 | 17.9 | 18,821 |
| infusion related reactionSignal | 1,112 | 18.7 | 17.6 | 18,344 |
| alopeciaSignal | 1,412 | 7.9 | 7.5 | 8,566 |
| hypersensitivitySignal | 1,248 | 7.4 | 7.0 | 6,933 |
| decreased appetiteSignal | 1,172 | 5.6 | 5.3 | 4,399 |
| pyrexiaSignal | 1,734 | 5.5 | 5.3 | 6,482 |
| vomitingSignal | 1,605 | 3.8 | 3.6 | 3,299 |
| rashSignal | 1,330 | 3.4 | 3.2 | 2,232 |
| dyspnoeaSignal | 1,696 | 3.3 | 3.1 | 2,769 |
| pruritusSignal | 1,138 | 3.3 | 3.1 | 1,801 |
| nauseaSignal | 2,321 | 3.2 | 3.1 | 3,681 |
| fatigueSignal | 2,054 | 2.9 | 2.8 | 2,641 |
| diarrhoeaSignal | 1,674 | 2.8 | 2.7 | 2,063 |
| pain | 1,097 | 2.0 | 1.8 | 529 |
| off label use | 1,489 | 1.9 | 1.8 | 622 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.